Followers | 845 |
Posts | 34218 |
Boards Moderated | 17 |
Alias Born | 03/22/2016 |
Monday, October 28, 2024 6:01:20 AM
Recent VIRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:39:52 PM
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives • GlobeNewswire Inc. • 12/26/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2024 10:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2024 09:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 10:20:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2024 12:30:08 PM
- Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 09:46:38 PM
- Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma • GlobeNewswire Inc. • 11/06/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 10:10:04 PM
- Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:15:25 AM
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2024 11:05:00 AM
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan • GlobeNewswire Inc. • 08/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:46:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:12:33 PM
- Viracta Therapeutics Announces New Employment Inducement Grants • GlobeNewswire Inc. • 05/17/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:26:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:23:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:34:41 PM
- Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:04:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:34:03 PM
- Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
The Crypto Company Highlights Blockchain Training Alliance's Successes and Momentum for 2025 • CRCW • Dec 26, 2024 8:58 AM
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM
UAV Corp's (UMAV), Skyborne Technology to Build "SKY" Hangar at Its Costin Airport Scheduled for Groundbreaking Ceremony Winter 2025 • UMAV • Dec 20, 2024 8:30 AM